Skip to main content
Premium Trial:

Request an Annual Quote

Ocimum Biosolutions to Offer NuGen's Ovation System in India

NEW YORK (GenomeWeb News) — Ocimum Biosolutions has become authorized by NuGen to provide sample preparation services in India using NuGen’s Ovation Systems, Hyderabad, India-based Ocimum said today.
Ocimum said it will now be able to offer the Ovation service to researchers who are conducting gene expression profiling studies from a range of sample types, such as small, compromised, or formalin-fixed, paraffin-embedded tissues.
NuGen representatives will provide Ocimum with specialized training to ensure their proficiency in generating high quality data from customer samples. The two companies also will work together to develop additional resources for customers including online seminars and technology updates.
The Ovation Systems are designed to be used in a range of sample types, including FFPE tissues, whole blood, tissue biopsies, later-captured micro-dissected cells, and sorted cells.
“With India's rapidly growing number of partnerships with global pharma companies, our alliance will significantly contribute to the success of customers' development and collaboration programs,” Sue Pandey, VP of field operations for San Carlos, Calif.-based NuGen, said in a statement.
Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.